The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004

被引：24

作者：

Bacher, Ulrike ^{[1
]}

Klyuchnikov, Evgeny ^{[1
,2
]}

Zabelina, Tatjana ^{[1
]}

Ottinger, Hellmut ^{[3
,4
]}

Beelen, Dietrich W. ^{[3
,4
]}

Schrezenmeier, Hubert ^{[3
,4
,5
]}

Ehninger, Gerhard ^{[3
,4
,6
]}

Mueller, Carlheinz ^{[3
,4
]}

Berger, Juergen ^{[7
]}

Suttorp, Meinolf ^{[8
]}

Kolb, Hans-Jochem ^{[9
]}

Kroeger, Nicolaus ^{[1
]}

Zander, Axel R. ^{[1
]}

机构：

[1] Univ Canc Ctr Hamburg UCCH, Interdisziplinare Klin Stammzelltransplantat, D-20246 Hamburg, Germany

[2] State Pavlovs Med Univ, Klin Stammzelltransplantat, St Petersburg, Russia

[3] Univ Klinikum Essen, DRST, KMT Klin, Ulm, Germany

[4] ZKRD, Ulm, Germany

[5] Univ Ulm, Inst Klin Transfus Med & Immungenet Ulm, Ulm, Germany

[6] Univ Klinikum Carl Gustav Carus Dresden, Med Klin & Poliklin 1, Dresden, Germany

[7] Univ Hamburg, Zentrum Expt Med, Inst Med Biometrie & Epidemiol, Hamburg, Germany

[8] Carl Gustav Carus Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany

[9] Univ Munich, Med Klin 3, Munich, Germany

来源：

ANNALS OF HEMATOLOGY | 2009年 / 88卷 / 12期

关键词：

Allogeneic stem cell transplantation (SCT); Chronic myeloid leukemia (CML); Dose-reduced conditioning (RIC); Myeloablative conditioning; German Registry of Stem Cell Transplantation (DRST); CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; IMMUNOGENETIC DONOR SEARCH; DISEASE-FREE-SURVIVAL; REDUCED-INTENSITY; IMATINIB MESYLATE; BCR-ABL; HEMATOLOGIC MALIGNANCIES; FOLLOW-UP; THERAPY;

D O I：

10.1007/s00277-009-0737-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Due to the recent changes in the indication to allogeneic stem cell transplantation (SCT) in chronic myeloid leukemia (CML), we retrospectively analyzed 1,716 patients with different CML stages who received an allograft from related (n = 767) or unrelated donors (n = 938) within the German Registry of Stem Cell Transplantation (DRST) from 1998 to 2004. Myeloablative conditioning was performed in 724/871 cases (83%), dose-reduced conditioning in 147/871 (17%). Annual transplantations were decreasing from 357 to 98 (28%) in the period of study, but the proportion of advanced cases was increasing from 32% (112/346) to 53% (50/94) of all SCTs. Stage of disease, intervals from diagnosis, and patients' age were independent prognostic parameters, while peripheral stem cells and unrelated transplantation seemed equal to bone marrow/related transplantation. This study demonstrates that allo-SCT still has an important role in advanced CML, which emphasizes the need for optimized transplantation strategies for these high-risk patients.

引用

页码：1237 / 1247

页数：11

共 34 条

[11]

Faber E, 2007, NEOPLASMA, V54, P443

[12] Chronic myeloid leukemia: Standard treatment options [J].

Frame, David .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 :S10-S14

[13] Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia [J].

Giralt, Sergio A. ;

Arora, Mukta ;

Goldman, John M. ;

Lee, Stephanie J. ;

Maziarz, Richard T. ;

McCarthy, Philip L. ;

Sobocinski, Kathleen A. ;

Horowitz, Mary M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) :461-467

[14] Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors [J].

Gratwohl, A. ;

Baldomero, H. ;

Frauendorfer, K. ;

Urbano-Ispizua, A. ;

Niederwieser, D. .

BONE MARROW TRANSPLANTATION, 2007, 39 (02) :71-87

[15] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].

Gratwohl, A ;

Hermans, J ;

Goldman, JM ;

Arcese, W ;

Carreras, E ;

Devergie, A ;

Frassoni, F ;

Gahrton, G ;

Kolb, H ;

Niederwieser, D ;

Ruutu, T ;

Vernant, JP ;

de Witte, T ;

Apperley, J .

LANCET, 1998, 352 (9134) :1087-1092

[16]

Gratwohl A, 2006, HAEMATOLOGICA, V91, P513

[17] Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure [J].

Jabbour, Elias ;

Cortes, Jorge ;

Kantarjian, Hagop M. ;

Giralt, Sergio ;

Jones, Dan ;

Jones, Roy ;

Giles, Francis ;

Andersson, Borje S. ;

Champlin, Richard ;

de Lima, Marcos .

BLOOD, 2006, 108 (04) :1421-1423

[18] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance [J].

Kantarjian, Hagop M. ;

Giles, Francis ;

Gattermann, Norbert ;

Bhalla, Kapil ;

Alimena, Giuliana ;

Palandri, Francesca ;

Ossenkoppele, Gert J. ;

Nicolini, Franck-Emmanuel ;

O'Brien, Stephen G. ;

Litzow, Mark ;

Bhatia, Ravi ;

Cervantes, Francisco ;

Haque, Ariful ;

Shou, Yaping ;

Resta, Debra J. ;

Weitzman, Aaron ;

Hochhaus, Andreas ;

le Coutre, Philipp .

BLOOD, 2007, 110 (10) :3540-3546

[19] Diagnosis and management of chronic myeloid leukemia - A survey of American and European practice patterns [J].

Kantarjian, Hagop M. ;

Cortes, Jorge ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Baccarani, Michele ;

Lokey, Lee .

CANCER, 2007, 109 (07) :1365-1375

[20] Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia [J].

Kantarjian, HM ;

O'Brien, S ;

Cortes, JE ;

Giralt, SA ;

Rios, MB ;

Shan, JQ ;

Giles, FJ ;

Thomas, DA ;

Faderl, S ;

De Lima, M ;

Garcia-Manero, G ;

Champlin, R ;

Arlinghaus, R ;

Talpaz, M .

BLOOD, 2002, 100 (05) :1590-1595

← 1 2 3 4 →